愛德華生命科學引領對抗心臟瓣膜疾病
愛德華生命科學公司致力於提升台灣對心臟瓣膜疾病的認識，並擴大治療的可及性，目標是在2029年前將瓣膜置換手術的數量增加一倍。
healthcare
Edwards Lifesciences Leads the Fight Against Heart Valve Disease
Edwards Lifesciences is raising awareness and expanding treatment access for underdiagnosed Heart Valve Disease in Taiwan, aiming to double valve replacements by 2029.
Haleon Delivers Everyday Health With Humanity
Despite notable advancements in medicine and technology in recent years, access to basic healthcare remains a global issue. The private sector’s role in citizen health is therefore becoming progressively essential to reduce part of the burden on the public healthcare system and meet growing needs for preventive care. To address these issues, leading consumer health…
Behavioral Telehealth Faces Growth Barriers
The increasing need for therapy and pandemic restrictions have spurred the growth of remote counseling. In Taiwan, clinicians and entrepreneurs battle bureaucratic barriers to reach those in need of care. When Taiwan went into a Level 3 pandemic alert that initiated a near-lockdown in the spring of 2021, counselors at schools and colleges were abruptly…
Elevating Patient Care with Access to Innovative Technology
The world of patient care is constantly evolving, thanks to the hard work, continuous innovation, and collaborative spirit of doctors, international healthcare providers, patient advocacy groups, and governments. To showcase some of the latest developments in this sector and their potential benefits for Taiwanese patients, AmCham Taiwan and the American Institute in Taiwan jointly held…
Improving Taiwan’s Healthcare R&D Environment Requires Reform
For multinational pharmaceutical companies, Taiwan has proven itself to be a very attractive investment destination in the Asia Pacific. The island’s sizeable pool of high-quality STEM talent, its extensive expertise in and productive environment for conducting clinical trials, active government-industry-academia cooperation in medical research, and advanced bio-ICT capacity are just a few of the qualities…
Preventing Intraoperative Complications with AI
The use of artificial intelligence (AI) technologies in critical care has potentially lifesaving outcomes for long-term disease prevention and critical decisions during surgery. AI technologies can help medical professionals find biomarkers of disease, identify target molecules, discover drug candidates, speed up clinical trials, and even monitor and predict epidemic outbreaks. There is also a distinct…
Taiwan’s Clinical Trials Landscape Weathers the COVID Era
The island’s effective management of the pandemic has helped boost its attractiveness as a destination for international healthcare companies to conduct clinical trials of new drugs. But to remain competitive post-COVID, Taiwan may need to take some additional steps. Within the global healthcare industry, one of the areas in which the COVID-19 pandemic has had…
Pfizer Gears up for Life-changing Breakthroughs
In the 60 years since Pfizer set up its first factory in Taiwan, the company has relentlessly pursued life-changing pharmaceutical and biotechnological breakthroughs. The company’s most important accomplishment in Taiwan, however, is its contribution to improving patients’ quality of life through the introduction to the market of the most advanced, innovative drugs, notes Country Manager…
MSD is a Committed Partner in Fostering Innovation
After nearly two years, COVID-19 continues to impact countries around the world. The pandemic has also highlighted the vital role of healthcare companies in developing and ensuring the equitable distribution of life-saving medicines. Among those involved in the effort to stop the spread and negative effects of coronavirus is global pharmaceutical firm Merck, Sharp, and…